ESC 365 - Therapeutic role of Prostaglandin E2 receptor 4 stimulation in inflammatory cardiomyopathy

Back

ESC Premium Access

Therapeutic role of Prostaglandin E2 receptor 4 stimulation in inflammatory cardiomyopathy

Session: Novel therapies for heart failure in the early pipeline

Topic: Pharmacotherapy

Speaker: Doctor T. Akira (Yokohama, JP)

Event: ESC Congress 2021 - The Digital Experience

Presentation

About the speaker

Doctor Takakuma Akira

Yokohama City University Hospital, Yokohama (Japan)

0 follower

2 more presentations in this session

Low level transcutaneous vagus nerve stimulation reverses cardiac dysfunction and changes left ventricular gene expression in a rat model of heart failure with preserved ejection fraction

Speaker: Doctor M. Niewiadomska (Oklahoma City, US)

Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts

Speaker: Professor A. Shiraki (Saga, JP)

Access the full session

Novel therapies for heart failure in the early pipeline

Speakers: Doctor T. Akira, Doctor M. Niewiadomska, Professor A. Shiraki

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

ESC Premium Access

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

27 August 2021

Therapeutic role of Prostaglandin E2 receptor 4 stimulation in inflammatory cardiomyopathy

About the speaker

Doctor Takakuma Akira

2 more presentations in this session

Low level transcutaneous vagus nerve stimulation reverses cardiac dysfunction and changes left ventricular gene expression in a rat model of heart failure with preserved ejection fraction

Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts

Access the full session

Novel therapies for heart failure in the early pipeline

About the event

ESC Congress 2021 - The Digital Experience

Related content

Endotrophin is significantly associated with disease severity and increased risk of adverse outcome in HFpEF but not in HFrEF patients

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

Additive prognostic value of cardiac biomarkers in patients with chronic obstructive pulmonary disease and heart failure

This platform is supported by